- Report
- September 2019
- 302 Pages
Global
From €2279EUR$2,395USD£1,951GBP
- Report
- February 2023
- 290 Pages
Global
From €4775EUR$5,194USD£3,950GBP
- Report
- March 2023
- 334 Pages
Global
From €4710EUR$4,950USD£4,033GBP
- Report
- May 2020
- 67 Pages
Global
From €4710EUR$4,950USD£4,033GBP
- Report
- April 2020
- 141 Pages
Global
From €4710EUR$4,950USD£4,033GBP
- Report
- February 2023
- 120 Pages
Global
From €5661EUR$5,950USD£4,847GBP
- Report
- December 2021
- 109 Pages
Global
From €2617EUR$2,750USD£2,240GBP
€5233EUR$5,500USD£4,481GBP
- Report
- February 2021
- 342 Pages
Global
From €3568EUR$3,750USD£3,055GBP
- Report
- March 2018
- 15 Pages
Global
- Report
- February 2018
- 15 Pages
Global
- Report
- April 2024
- 175 Pages
From €4757EUR$5,000USD£4,073GBP
- Report
- August 2022
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Report
- August 2022
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Report
- August 2022
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Report
- August 2022
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Report
- August 2022
- 110 Pages
Global
From €4519EUR$4,750USD£3,870GBP
- Report
- June 2022
- 118 Pages
Global
From €4519EUR$4,750USD£3,870GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €3092EUR$3,250USD£2,648GBP
The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more